NGL Fine-ChemNSE:NGLFINE -2.72%78 Net Margin % is 9.04% as of Mar. 2026, which is 24% below its 10-year median of 11.87. GuruFocus rates NSE:NGLFINE with a GF Score™ of 78/100 and a GF Value™ of ₹2,803.99 (Fairly Valued). The stock has 8 warning signs investors should review. Among 956 Drug Manufacturers companies, NGL Fine-Chem ranks better than 62.34% on this metric.
Net margin is calculated as Net Income divided by its Revenue. NGL Fine-Chem's Net Income for the
three
months ended in Mar. 2026 was ₹135 Mil. NGL Fine-Chem's Revenue for the
three
months ended in Mar. 2026 was ₹1,492 Mil. Therefore, NGL Fine-Chem's net margin for the quarter that ended in Mar. 2026 was 9.04%.
The historical rank and industry rank for NGL Fine-Chem's Net Margin % or its related term are showing as below:
NSE:NGLFINE'
s Net Margin % Range Over the Past 10 Years
Min: 5.6 Med: 11.87 Max: 22.24
Current: 9.59
NSE:NGLFINE's Net Margin % is ranked better than 62.34% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs NSE:NGLFINE: 9.59
NGL Fine-Chem (NSE:NGLFINE) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
NGL Fine-Chem Net Margin % Related Terms
NGL Fine-Chem Net Margin % Historical Data
* Premium members only.
The historical data trend for NGL Fine-Chem's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NGLFINE vs LLY, JNJ, ABBV: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, NGL Fine-Chem's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NGL Fine-Chem Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's Net Margin % distribution charts can be found below:
* The bar in red indicates where NGL Fine-Chem's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGL Fine-Chem (NSE:NGLFINE) has a Net Margin % of 9.04% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on NGL Fine-Chem and its competitors. This is 24% below median its historical median of 11.87. Over the past decade, NGL Fine-Chem's Net Margin % has ranged from 5.60 to 22.24. According to the industry distribution chart, NGL Fine-Chem ranks #360 out of 956 companies in the Drug Manufacturers industry, placing it in the top 37.7%.
Is NGL Fine-Chem's Net Margin % too high?
NGL Fine-Chem's current Net Margin % of 9.04% is 24% below median its 10-year median of 11.87. Over the past 10 years, this metric has ranged from a low of 5.60 to a high of 22.24. The Drug Manufacturers industry median Net Margin % is 5.56. NGL Fine-Chem's value of 9.04% is 62.6% above this industry median. Based on the distribution chart, NGL Fine-Chem ranks #360 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, NGL Fine-Chem has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, NGL Fine-Chem ranks #360 out of 956 companies for Net Margin %. This puts NGL Fine-Chem in the upper half of its industry. The industry median Net Margin % is 5.56. NGL Fine-Chem's value of 9.04% is 62.6% above this benchmark. Historically, NGL Fine-Chem's own Net Margin % has ranged from 5.60 to 22.24 over the past decade. While the company's 10-year median is 11.87 vs. the industry median of 5.56, NGL Fine-Chem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NGL Fine-Chem's current Net Margin % of 9.04% is 62.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on NGL Fine-Chem and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NGL Fine-Chem's current Net Margin % is 9.04%, which is 24% below median its own 10-year median of 11.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,803.99, compared to a current price of ₹2,989.90 — trading 6.6% above its estimated fair value. The current Net Margin % is 9.04%, which is 24% below median its 10-year median of 11.87 and 62.6% above the Drug Manufacturers industry median of 5.56. NGL Fine-Chem's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current Net Margin % is 9.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?
Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued.
The current stock price of ₹2,989.90 is trading 6.6% above its estimated GF Value™ of ₹2,803.99.
GuruFocus considers NGL Fine-Chem to be Fairly Valued.
Key valuation signals for NSE:NGLFINE:
Net Margin %: 9.04% (24% below median its 10-year median of 11.87)
GF Value™: ₹2,803.99 vs. price of ₹2,989.90 (6.6% above fair value)
Industry Position: 62.6% above the Drug Manufacturers median (#360 of 956)
No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
78GF Score
Get the complete analysis for NSE:NGLFINE
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NGLFINE has been successfully added to your 
